vTv Therapeutics Inc. - Class A Common Stock (VTVT)

vTv Therapeutics (NASDAQ:VTVT) used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician market-research findings, and review the development program for its investigational oral therapy, cadisegliatin. Paul Sekhri, th

vTv Therapeutics just reported results for the second quarter of 2024.

vTv Therapeutics just reported results for the first quarter of 2024.

vTv Therapeutics reports Q2 2025 loss of $0.92 per share, missing estimates. Revenue at $0 as expected. Shares rise slightly amid focus on Phase 3 diabetes trial progress.

vTv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month timeline to accelerate key studies.

vTv Therapeutics faces a setback as the FDA places a clinical hold on its cadisegliatin program, impacting the CATT1 Phase 3 trial for type 1 diabetes.

LuxUrban Hotels stock is down on Monday after the company priced a public offering of LUXH shares below its prior closing price.

VTv Therapeutics stock is falling on Monday as VTVT investors react to the company's cadisegliatin clinical program being put on hold.

Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!

Many healthcare stocks have extremely bright outlooks and very low valuations. Here are three top healthcare stocks to buy. 

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&P 500 also fell, dropping, 0.18% to 5,068.92.